Funding for this research was provided by:
U.S. Department of Defense (AR140087 (Contract W81XWH-15-1-0156))
Received: 12 November 2020
Accepted: 14 May 2021
First Online: 25 May 2021
Change Date: 23 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/S13229-021-00451-9
: The study was approved by the Institutional Review Boards (IRB) at the U.S. Department of Defense (A-18817.a), UMass Medical School (H00007832) and Johns Hopkins University (00084331), along with consent and assent forms. Approval was granted by the Food and Drug Administration (IND 127062). All participants and their caregivers were consented at the screening visit prior to assessments, examinations, urine collections and phlebotomies.
: AWZ reports giving testimony in legal proceedings on behalf of plaintiffs and defendants in matters related to pediatric neurology and Autism Spectrum Disorder. JWF retired from the full-time faculty at Johns Hopkins in mid-2020, and now serves as a scientific advisor to Brassica Protection Products LLC (Baltimore, MD, USA), which produces a glucoraphanin-rich broccoli seed extract that it supplies to the supplement industry. AWZ is named on a patent on the use of sulforaphane for the treatment of autism that has been assigned to Johns Hopkins University.
: Not applicable.